Hospira Desferrioxamine Mesilate for Injection, BP 500 mg/vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

desferrioxamine mesilate, Quantity: 500 mg

Available from:

Hospira Australia Pty Ltd

INN (International Name):

desferrioxamine mesilate

Pharmaceutical form:

Injection, powder for

Composition:

Excipient Ingredients: water for injections

Administration route:

Subcutaneous, Intravenous Infusion, Intramuscular, Intraperitoneal

Units in package:

10 x 500 mg

Class:

Medicine Listed (Export Only)

Prescription type:

(S1) This Schedule is intentionally blank

Therapeutic indications:

a) Acute iron intoxication. b) Chronic iron overload due to transfusion-dependent anemias. c) Diagnosis of aluminium overload (desferrioxamine infusion test). d) Chronic aluminium overload in patients with ESRF under maintenance dialysis. In cases of acute iron intoxication, desferrioxamine is an adjunct to, and not a substitute for, standard therapeutic measures whuich may include: i) Induction of emesis. ii) Gastric lavage. iii) Maintenance of clear airways. iv) Control of peripheral vascular failure. v) Correction of acidosis.

Product summary:

Visual Identification: A white to cream powder or lyophilized plug; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store between 15-25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Listed (Export Only)

Authorization date:

2007-09-11